AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01223755
Drug: conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment relates usually to the administration of antihypertensive drugs for patients with high blood pressure. Thus, for the present study, no major change in antihypertensive treatment should be introduced throughout the whole study period unless deemed clinically necessary (the reasons of the changes should be, however, clearly explained in the CRF). Only small changes in the doses of the ongoing treatments are recommended in order to maintain the same level of blood pressure control (target systolic/diastolic blood pressure \<130/80 mmHg). This approach is aimed to minimize the confounding effect of any change in concomitant treatments on some efficacy variables (such as urinary protein excretion rate).
Trial: NCT01448200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules
Trial: NCT04154501
Drug: CNTX-6016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Dose CNTX-6016
Trial: NCT02284139
Drug: Arm Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF Ointment 0ppm evenly apply to skin lesion every 12 hr/ day
Trial: NCT00867360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication
Trial: NCT01451541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - one dose per nostril
Trial: NCT01225523
Drug: Paclitaxel; Cisplatin; 5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
Trial: NCT01225523
Drug: Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
Trial: NCT00510627
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care chemotherapy regimen
Trial: NCT02768974
Drug: OPRX-106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral delivery, once daily.
Trial: NCT01002092
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).
Trial: NCT02736019
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women will receive oral Celecoxib 200mg 2 hours before the procedure
Trial: NCT02736019
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
Trial: NCT02736019
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
Trial: NCT03324139
Drug: Low molecular weight heparin
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
Trial: NCT03324139
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
Trial: NCT01739647
Drug: AZD3293
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT01739647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT00229944
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01954693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg daily administered for 6 months as two oral 2.5 mg tablets once daily.
Trial: NCT04269395
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention will be administered as a part of this study. Participants who received vehicle cream in RD.06.SPR.112199 study and achieved complete response, will be rolled over in the study.
Trial: NCT00524056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two placebo tablets twice per day
Trial: NCT00159432
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00887861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03815903
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2
Trial: NCT02542254
Drug: RPL554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg RPL554 administered using a nebuliser
Trial: NCT02542254
Drug: Salbutamol matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pMDI
Trial: NCT02542254
Drug: RPL554 matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised placebo
Trial: NCT01139762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally, once daily for 26 weeks
Trial: NCT02313545
Drug: IZN-6NVS Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra.~Cream concentration: 5%
Trial: NCT01764633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Trial: NCT00388778
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00467571
Drug: lansoprazole, clarithromycin, amoxycillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
Trial: NCT00008060
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00008060
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00008060
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00008060
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04219150
Drug: Fluid and Catheter Treatment Trial FACTT Lite
RxNorm normalized name: Lite 'N Foamy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The FACTT Lite provided three possible instructions determined by the CVP and urine output: furosemide administration, fluid bolus, or no intervention. FACTT Lite contained instructions to withhold furosemide until the patient achieved a mean arterial pressure greater than 60 mmHg off of vasopressors for at least 12 h.
Trial: NCT03273595
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02658214
Drug: cisplatin + 5-fluorouracil (5FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT01472432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is added to the standard good medical practice. Plus Metformin and/or Sulfonylurea
Trial: NCT03098485
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 days of azithromycin administration
Trial: NCT03209115
Drug: combination of calcium hydroxide and chlorhexidine
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placement of calcium hydroxide and chlorhexidine as intracanal medicament after removal of old filling and mechanical preparation of root canal
Trial: NCT03209115
Drug: Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placement of calcium hydroxide as intracanal medicament after removal of old filling and mechanical preparation of root canal
Trial: NCT03234907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab placebo-matching
Trial: NCT02132130
Drug: CGF166
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
Trial: NCT02483195
Drug: 200mg Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
Trial: NCT04132115
Drug: Gentamicins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
Trial: NCT04132115
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
Trial: NCT01634685
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
Trial: NCT04224584
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will act as a control for duloxetine.
Trial: NCT04218487
Drug: Xuefu-Zhuyu Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with 2.4g (6 capsules) of XFZY three times daily for 12 weeks.
Trial: NCT04218487
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with 2.4g (6 capsules) of placebo three times daily for 12 weeks.
Trial: NCT02108639
Drug: DCV 3DAA FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01951209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT04464369
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pills matching the look and weight of the itopride tablets
Trial: NCT01513239
Drug: SOC
RxNorm normalized name: Isocet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Trial: NCT01828294
Drug: Subcutaneous immunoglobulins
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
Trial: NCT02346630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules daily for 3 weeks.
Trial: NCT02346630
Drug: Levodopa / Carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.
Trial: NCT00109512
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02152696
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
Trial: NCT03891095
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasally administrated and orally administered
Trial: NCT00198133
Drug: Premetrexed (Alimta)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed will be 500 mg/m2 IV every 3 weeks
Trial: NCT03960801
Drug: Remifentanil group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
Trial: NCT03960801
Drug: neuromuscular blockade group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
Trial: NCT01949922
Drug: Analgesia
RxNorm normalized name: Analgesia Creme Rub
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
Trial: NCT02364258
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
Trial: NCT01067950
Drug: Intensive Insulin Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00766220
Drug: SIR-spheres Agent Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.
Trial: NCT00797472
Drug: R-mabHD
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
Trial: NCT03158376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01539564
Drug: Minocycline HCl Microspheres
RxNorm normalized name: minocycline HCl microspheres
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01519830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution
Trial: NCT02959879
Drug: Standard adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 cycles of standard adjuvant chemotherapy are administrated
Trial: NCT02959879
Drug: adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 cycles of standard adjuvant chemotherapy are administrated
Trial: NCT02638922
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol containing compounds administered orally in a non-randomized manner.
Trial: NCT00774540
Drug: 1 Ketorolac intraarticular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac intraarticular 5 mg
Trial: NCT00774540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT03558295
Drug: Oral Anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: warfarin, dabigatran, rivaroxaban, edoxaban
Trial: NCT03043131
Drug: Plasmalyte A
RxNorm normalized name: PLASMALYTE A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients
Trial: NCT03043131
Drug: Ringer Lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients
Trial: NCT02827097
Drug: denogan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of denogan
Trial: NCT04146805
Drug: Control: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized in a 6:2 ratio to control (matched placebo). Study drug will be administered orally once a with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
Trial: NCT01195233
Drug: bioxtra
RxNorm normalized name: Bioxtra
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spray /mouth rinse
Trial: NCT02906059
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03639389
Drug: Analgesics
RxNorm normalized name: ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients
Trial: NCT00577993
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2 IV Days 2 \& 3 of 1st Sequence.
Trial: NCT00171145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily
Trial: NCT00577993
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2 IV Day 2 of 1st Sequence.
Trial: NCT01663662
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03421119
Drug: Sulfonylurea/non-sulfonylurea insulin secretagogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study.
Trial: NCT03357380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
Trial: NCT02508805
Drug: Neuromultivit
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01978873
Drug: Androgen deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
Trial: NCT01159873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.
Trial: NCT02117830
Drug: Androxal 250 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02117830
Drug: Placebo Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00414479
Drug: praziquantl, iron, ACT
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02017873
Drug: Peroxide Carbamide 10% - Dental bleaching treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
Trial: NCT03784495
Drug: Melatonin 1mg
RxNorm normalized name: MELATONIN 1MG CAP/TAB
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg/day 30 minutes before sleep
Trial: NCT04160091
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection
Trial: NCT00031863
Drug: rofecoxib
RxNorm normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01659775
Drug: Zofran inj.+Zofran tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5.
Trial: NCT02217566
Drug: Androgen deprivation therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.
Trial: NCT02480634
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
Trial: NCT02144051
Drug: AZD5312
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.
Trial: NCT04393610
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
Trial: NCT02004769
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.